NHS guidance lists common effects such as pain, swelling, or itching at the injection site and nausea
The peptide completed six randomized, double-blind, placebo-controlled clinical trials involving over 900 participants, establishing excellent safety and tolerability
The treatment may include injections that are given every day for 10 days then tailored as per the patients need and inject regularly every few weeks or months
Since one capsule contains 50mg of 5-amino-1MQ, subjects require one to three capsules daily
Long-term safety data beyond 24 weeks is limited
Pharmacokinetic Profile Route of Administration Oral Half-Life 6-8 hours Route of Administration: Oral, Intravenous Dosing Frequency: Once per day Half-Life: ~6-8 hours Formulation & Handling Soluble in saline